Enhancing specialist competence in clinical pathways for left ventricular hypertrophy: design and evaluation of a

Yanjia Chen1, Jie Jiang2, Wei Jin3

  • 1Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025, P.R. China.

Insights

A new competency-based curriculum improved cardiologists' knowledge and diagnostic skills for left ventricular hypertrophy (LVH) and its rare causes. This program standardizes clinical pathways, enhancing care coordination for LVH patients.

Area of Science:

  • Cardiology
  • Medical Education
  • Health Services Research

Background:

  • Left ventricular hypertrophy (LVH) presents diverse etiologies, leading to diagnostic challenges and delays.
  • Variability in specialist reasoning and inconsistent clinical pathways contribute to diagnostic gaps in LVH.
  • Standardizing diagnostic approaches is crucial for improving patient outcomes in LVH.

Purpose of the Study:

  • To design and evaluate a competency-based curriculum for standardizing LVH diagnostic pathways.
  • To assess the curriculum's impact on physician knowledge, diagnostic reasoning, and clinical confidence.
  • To explore the feasibility of a health services intervention for LVH care.

Main Methods:

  • A blended learning curriculum was developed for 45 cardiologists, focusing on patient-centered care and multidisciplinary collaboration.
  • The program included guideline reinforcement, genetics-focused learning, case discussions, and pathway design exercises.
  • Outcomes were measured via pre/post-training knowledge tests, case evaluations, and confidence surveys.

Main Results:

  • Mean knowledge scores significantly increased from 62% to 86% (p < 0.001).
  • Accurate identification of rare LVH etiologies improved from 35% to 78%.
  • Participants reported significantly higher diagnostic confidence and high course satisfaction (92%).

Conclusions:

  • The competency-based curriculum demonstrated short-term improvements in specialist knowledge and diagnostic reasoning for LVH.
  • The program has the potential to reduce practice variability and standardize clinical pathways for LVH.
  • This intervention may enhance referral consistency and inter-provider care coordination for LVH patients.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...